Compound A22 also performed well in a NAFLD/NASH mouse model where treatment led to elevated BCL2 levels, less apoptosis, and decreased markers of hepatocyte injury and metabolic syndrome (e.g., weight gain not associated with food intake, insulin resistance, and elevated serum cholesterol and triglycerides). This evidence concerns the gene BCL2 and metabolic dysfunction-associated steatohepatitis.